000132645 001__ 132645
000132645 005__ 20240229105025.0
000132645 0247_ $$2doi$$a10.1093/ageing/afx157
000132645 0247_ $$2pmid$$apmid:29036424
000132645 0247_ $$2ISSN$$a0002-0729
000132645 0247_ $$2ISSN$$a1468-2834
000132645 0247_ $$2altmetric$$aaltmetric:26714704
000132645 037__ $$aDKFZ-2018-00305
000132645 041__ $$aeng
000132645 082__ $$a610
000132645 1001_ $$aHajek, André$$b0
000132645 245__ $$aFrailty and healthcare costs-longitudinal results of a prospective cohort study.
000132645 260__ $$aOxford$$bOxford Univ. Press$$c2018
000132645 3367_ $$2DRIVER$$aarticle
000132645 3367_ $$2DataCite$$aOutput Types/Journal article
000132645 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1539690078_28062
000132645 3367_ $$2BibTeX$$aARTICLE
000132645 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132645 3367_ $$00$$2EndNote$$aJournal Article
000132645 520__ $$ato investigate how frailty and frailty symptoms affect healthcare costs in older age longitudinally.data were gathered from a prospective cohort study in Saarland, Germany (two waves with 3-year interval, n = 1,636 aged 57-84 years at baseline). Frailty was assessed by the five Fried frailty criteria. Frailty was defined as having at least three criteria, the presence of 1-2 criteria as pre-frail. Healthcare costs were quantified based on self-reported healthcare use in the sectors of inpatient treatment, outpatient treatment, professional nursing care and informal care as well as the provision of pharmaceuticals, medical supplies and dental prostheses.while the onset of pre-frailty did not increase (log) total healthcare costs after adjusting for potential confounders including comorbidity, progression from non-frailty to frailty was associated with an increase in total healthcare costs (for example, costs increased by ~54 and 101% if 3 and 4 or 5 symptoms were present, respectively). This association of frailty onset with increased healthcare costs was in particular observed in the inpatient sector and for informal nursing care. Among the frailty symptoms, the onset of exhaustion was associated with an increase in total healthcare costs, whereas changes in slowness, weakness, weight loss and low-physical activity were not significantly associated with an increase in total healthcare costs.our data stress the economic relevance of frailty in late life. Postponing or reducing frailty might be fruitful in order to reduce healthcare costs.
000132645 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132645 588__ $$aDataset connected to CrossRef, PubMed,
000132645 7001_ $$aBock, Jens-Oliver$$b1
000132645 7001_ $$0P:(DE-He78)97343bbd9545a4b87574e74329dabfd1$$aSaum, Kai-Uwe$$b2$$udkfz
000132645 7001_ $$aMatschinger, Herbert$$b3
000132645 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4
000132645 7001_ $$0P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aHolleczek, Bernd$$b5$$udkfz
000132645 7001_ $$aHaefeli, Walter E$$b6
000132645 7001_ $$aHeider, Dirk$$b7
000132645 7001_ $$aKönig, Hans-Helmut$$b8
000132645 773__ $$0PERI:(DE-600)2065766-3$$a10.1093/ageing/afx157$$gVol. 47, no. 2, p. 233 - 241$$n2$$p233 - 241$$tAge & ageing$$v47$$x1468-2834$$y2018
000132645 909CO $$ooai:inrepo02.dkfz.de:132645$$pVDB
000132645 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)97343bbd9545a4b87574e74329dabfd1$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132645 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132645 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)53e1a2846c69064e27790dbf349ccaec$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000132645 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132645 9141_ $$y2018
000132645 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000132645 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132645 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAGE AGEING : 2015
000132645 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132645 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132645 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000132645 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000132645 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132645 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132645 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132645 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132645 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132645 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132645 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132645 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lKlinische Epidemiologie und Alternsforschung$$x0
000132645 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000132645 980__ $$ajournal
000132645 980__ $$aVDB
000132645 980__ $$aI:(DE-He78)C070-20160331
000132645 980__ $$aI:(DE-He78)G110-20160331
000132645 980__ $$aUNRESTRICTED